131-I-meta-iodobenzylguanidine in treatment of malignant phaeochromocytomas. 1983

H Vetter, and M Fischer, and R Müller-Rensing, and W Vetter, and B Winterberg

UI MeSH Term Description Entries
D007462 Iodobenzenes Any derivative of BENZENE that contains IODINE.
D010673 Pheochromocytoma A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298) Pheochromocytoma, Extra-Adrenal,Extra-Adrenal Pheochromocytoma,Extra-Adrenal Pheochromocytomas,Pheochromocytoma, Extra Adrenal,Pheochromocytomas,Pheochromocytomas, Extra-Adrenal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000310 Adrenal Gland Neoplasms Tumors or cancer of the ADRENAL GLANDS. Adrenal Cancer,Adrenal Gland Cancer,Adrenal Neoplasm,Cancer of the Adrenal Gland,Neoplasms, Adrenal Gland,Adrenal Cancers,Adrenal Gland Cancers,Adrenal Gland Neoplasm,Adrenal Neoplasms,Cancer, Adrenal,Cancer, Adrenal Gland,Cancers, Adrenal,Cancers, Adrenal Gland,Neoplasm, Adrenal,Neoplasm, Adrenal Gland,Neoplasms, Adrenal
D019797 3-Iodobenzylguanidine A guanidine analog with specific affinity for tissues of the sympathetic nervous system and related tumors. The radiolabeled forms are used as antineoplastic agents and radioactive imaging agents. (Merck Index, 12th ed) MIBG serves as a neuron-blocking agent which has a strong affinity for, and retention in, the adrenal medulla and also inhibits ADP-ribosyltransferase. (3-Iodo-(131I)benzyl)guanidine,Iobenguane,MIBG,3-Iodobenzylguanidine, 123I Labeled,3-Iodobenzylguanidine, 125I Labeled,Iobenguane (131I),m-Iodobenzylguanidine,meta-Iodobenzylguanidine,123I Labeled 3-Iodobenzylguanidine,125I Labeled 3-Iodobenzylguanidine,3 Iodobenzylguanidine,3 Iodobenzylguanidine, 123I Labeled,3 Iodobenzylguanidine, 125I Labeled,m Iodobenzylguanidine,meta Iodobenzylguanidine

Related Publications

H Vetter, and M Fischer, and R Müller-Rensing, and W Vetter, and B Winterberg
February 1991, Cancer,
H Vetter, and M Fischer, and R Müller-Rensing, and W Vetter, and B Winterberg
January 1988, Progress in clinical and biological research,
H Vetter, and M Fischer, and R Müller-Rensing, and W Vetter, and B Winterberg
October 1986, Polski tygodnik lekarski (Warsaw, Poland : 1960),
H Vetter, and M Fischer, and R Müller-Rensing, and W Vetter, and B Winterberg
October 1990, Nederlands tijdschrift voor geneeskunde,
H Vetter, and M Fischer, and R Müller-Rensing, and W Vetter, and B Winterberg
January 1988, Panminerva medica,
H Vetter, and M Fischer, and R Müller-Rensing, and W Vetter, and B Winterberg
September 1984, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
H Vetter, and M Fischer, and R Müller-Rensing, and W Vetter, and B Winterberg
January 1986, Der Internist,
H Vetter, and M Fischer, and R Müller-Rensing, and W Vetter, and B Winterberg
January 1988, Klinische Padiatrie,
H Vetter, and M Fischer, and R Müller-Rensing, and W Vetter, and B Winterberg
January 1991, Annales de medecine interne,
H Vetter, and M Fischer, and R Müller-Rensing, and W Vetter, and B Winterberg
July 1984, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
Copied contents to your clipboard!